Milligan Michael Lee 4

4 · Neumora Therapeutics, Inc. · Filed May 30, 2025

Insider Transaction Report

Form 4

Period: 2025-05-28

Neumora Therapeutics, Inc.NMRA

Milligan Michael Lee

See Remarks

Transactions

Disposition to Issuer
Stock Option (Right to Buy)
2025-05-28−41,250→ 0 total
Exercise: $1.69Exp: 2034-02-14→ Common Stock (41,250 underlying)
Award
Stock Option (Right to Buy)
2025-05-28+400,000→ 400,000 total
Exercise: $0.72Exp: 2035-02-13→ Common Stock (400,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-05-28−85,391→ 0 total
Exercise: $1.69Exp: 2032-01-27→ Common Stock (85,391 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-05-28−38,234→ 0 total
Exercise: $1.69Exp: 2033-02-17→ Common Stock (38,234 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-05-28−28,675→ 0 total
Exercise: $1.69Exp: 2033-06-23→ Common Stock (28,675 underlying)
Award
Stock Option (Right to Buy)
2025-05-28+38,234→ 38,234 total
Exercise: $0.72Exp: 2033-02-17→ Common Stock (38,234 underlying)
Award
Stock Option (Right to Buy)
2025-05-28+28,675→ 28,675 total
Exercise: $0.72Exp: 2033-06-23→ Common Stock (28,675 underlying)
Award
Stock Option (Right to Buy)
2025-05-28+41,250→ 41,250 total
Exercise: $0.72Exp: 2034-02-14→ Common Stock (41,250 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-05-28−400,000→ 0 total
Exercise: $1.69Exp: 2035-02-13→ Common Stock (400,000 underlying)
Award
Stock Option (Right to Buy)
2025-05-28+85,391→ 85,391 total
Exercise: $0.72Exp: 2032-01-27→ Common Stock (85,391 underlying)

Footnotes (7)

[F1]25% of the shares subject to the option vest on the first anniversary measured from December 20, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
[F2]On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 7, all other terms of the option remain unchanged.
[F3]25% of the shares subject to the option vest on the first anniversary measured from February 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
[F4]25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the "Vesting Commencement Date'), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
[F5]25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
[F6]25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
[F7]On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026.

Documents

1 file

4
ownership.xmlPrimary
4